Literature DB >> 18095916

The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer.

Mark J McKeage1.   

Abstract

5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a vascular disrupting agent that has demonstrated efficacy in combination with taxane-based chemotherapy in patients with advanced cancer. Complementary modes of action, a lack of pharmacokinetic interaction and distinct adverse effect profiles provide a strong rationale for combining these anticancer agents. In a Phase II trial in men with hormone refractory prostate cancer, DMXAA (ASA404) in combination with docetaxel achieved a prostate-specific antigen response in more patients than docetaxel therapy alone, and was generally well tolerated. Further clinical evaluation of this combination in this patient population is warranted.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18095916     DOI： 10.1517/13543784.17.1.23

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.206


  11 in total

Review 1.  Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.

Authors:  Zhiyan Xiao; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-09-11       Impact factor: 12.944

2.  Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responses.

Authors:  Allison Marrero; Theresa Becker; Ulas Sunar; Janet Morgan; David Bellnier
Journal:  Photochem Photobiol       Date:  2011-06-13       Impact factor: 3.421

Review 3.  Future directions in castrate-resistant prostate cancer therapy.

Authors:  Emmanuel S Antonarakis; Michael A Carducci
Journal:  Clin Genitourin Cancer       Date:  2010-12-01       Impact factor: 2.872

Review 4.  The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.

Authors:  Dietmar W Siemann
Journal:  Cancer Treat Rev       Date:  2010-06-08       Impact factor: 12.111

Review 5.  Targeting angiogenesis for the treatment of prostate cancer.

Authors:  Emmanuel S Antonarakis; Michael A Carducci
Journal:  Expert Opin Ther Targets       Date:  2012-03-13       Impact factor: 6.902

6.  18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.

Authors:  Christoph Oehler; Joseph A O'Donoghue; James Russell; Pat Zanzonico; Sylvie Lorenzen; C Clifton Ling; Sean Carlin
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

7.  Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.

Authors:  Joseph Conlon; Dara L Burdette; Shruti Sharma; Numana Bhat; Mikayla Thompson; Zhaozhao Jiang; Vijay A K Rathinam; Brian Monks; Tengchuan Jin; T Sam Xiao; Stefanie N Vogel; Russell E Vance; Katherine A Fitzgerald
Journal:  J Immunol       Date:  2013-04-12       Impact factor: 5.422

8.  Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs.

Authors:  L-C Steve Wang; Lai-Ming Ching; James W Paxton; Philip Kestell; Rachel Sutherland; Li Zhuang; Bruce C Baguley
Journal:  Invest New Drugs       Date:  2008-08-12       Impact factor: 3.850

Review 9.  Novel targeted therapeutics for metastatic castration-resistant prostate cancer.

Authors:  Emmanuel S Antonarakis; Michael A Carducci; Mario A Eisenberger
Journal:  Cancer Lett       Date:  2009-08-29       Impact factor: 8.679

10.  Antitumor effects of combining docetaxel (taxotere) with the antivascular action of ultrasound stimulated microbubbles.

Authors:  David E Goertz; Margarita Todorova; Omid Mortazavi; Vlad Agache; Branson Chen; Raffi Karshafian; Kullervo Hynynen
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.